Form 4: Edwards Lifesciences Executive Exercises Stock Options and Sells Shares Under 10b5-1 Plan

Daniel J. Lippis, a CVP at Edwards Lifesciences, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• On March 7, 2024, Daniel J. Lippis, CVP of JAPAC at Edwards Lifesciences Corp, exercised employee stock options to acquire 1,715 shares of common stock at a price of $36.75 per share.
• Simultaneously, Lippis sold 1,715 shares of common stock at a price of $90.98 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on December 11, 2023.
• Following these transactions, Lippis directly owns 17,213.2105 shares of Edwards Lifesciences common stock and 1,714 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects routine transactions under a pre-arranged trading plan. There is no indication of positive or negative implications for the company's performance.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating a planned and transparent approach to stock transactions.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The use of a 10b5-1 plan is a common practice to avoid accusations of insider trading.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders as they represent routine trading activity by an executive.

Key Dates